Unlocking the Potential of ABHD13: A novel Drug Target and Biomarker

Target Name: ABHD13

NCBI ID: G84945

ABHD13

Unlocking the Potential of ABHD13: A novel Drug Target and Biomarker

Alpha/beta hydrolase domain-containing protein 13 (ABHD13) is a member of the N-terminal hydrolase family 13, which plays a crucial role in various physiological processes, including cell signaling, DNA repair, and inflammation. The encoded protein has unique structural features, including a N-terminal alpha-helical region, a hydrolase domain, and a C-terminal T-loop, which give it a unique 3D structure. Despite its importance in cellular processes, little is known about ABHD13, and it remains a challenging target for researchers.

The Drug Target Potential of ABHD13

The drug development process involves identifying potential drug targets and validating their suitability. ABHD13 is an attractive drug target due to its various functions in the cell. Its unique structure and location in the cell membrane make it an attractive target for small molecules, antibodies, or other therapeutic agents. Here are some potential drug targets for ABHD13:

1. Dysregulated cell signaling: ABHD13 is involved in various signaling pathways, including cell signaling, which is critical for cellular processes such as growth, differentiation, and survival. Disruptions in these signaling pathways can lead to diseases such as cancer, neurodegenerative diseases, and mental disorders. Targeting ABHD13 with small molecules or antibodies may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new therapeutic approaches.
2. DNA repair and genome stability: ABHD13 is involved in DNA repair and genome stability, which are critical for maintaining cellular health and preventing mutations that can lead to diseases. Disruptions in these processes can lead to mutations that can lead to cancer and other diseases. Targeting ABHD13 with small molecules or antibodies may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new therapeutic approaches.
3. Inflammation: ABHD13 is involved in the immune response and inflammation. Disruptions in these processes can lead to chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, and asthma. Targeting ABHD13 with small molecules or antibodies may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new therapeutic approaches.

The Biomarker Potential of ABHD13

ABHD13 is also an attractive biomarker for various diseases. Its unique structure and functions in the cell membrane make it an attractive target for diagnostic tools such as mass spectrometry (MS) and affinity purification mass spectrometry (AP-MS). Here are some potential biomarkers for ABHD13:

1. Biomarker for cancer: ABHD13 is involved in cell signaling and has been implicated in various cancer types, including breast, ovarian, and prostate cancers. Targeting ABHD13 with small molecules or antibodies may provide new insights into the underlying mechanisms of these cancers and may lead to the development of new therapeutic approaches.
2. Biomarker for neurodegenerative diseases: ABHD13 is involved in various signaling pathways, including the neurotrophic factor (NTF) pathway, which is critical for neuron survival and function. Disruptions in this pathway have been implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Targeting ABHD13 with small molecules or antibodies may provide new insights into the underlying mechanisms of these diseases and may lead to the development of new therapeutic approaches.
3. Biomarker for inflammatory diseases: ABHD13 is involved in the immune response and inflammation. Disruptions in

Protein Name: Abhydrolase Domain Containing 13

The "ABHD13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets